Our findings indicate that the inactivation of NOTCH1 alone, without concomitant inhibition of EGFR, may lead to unexpected outcomes in lung cancer by increasing ERBB3 to promote EGFR-mutated tumour growth, providing a caution against indiscriminate use of NOTCH inhibitors. Here, EGFR is linked to lung cancer.